Cobicistat; Darunavir Patent Expiration
Cobicistat; Darunavir is Used for managing HIV-1 infection in adults and pediatric patients. It was first introduced by Janssen Products Lp
Cobicistat; Darunavir Patents
Given below is the list of patents protecting Cobicistat; Darunavir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Prezcobix | US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Oct 06, 2032 | Janssen Prods |
| Prezcobix | US8148374 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Janssen Prods |
| Prezcobix |
US7700645 (Pediatric) | Pseudopolymorphic forms of a HIV protease inhibitor | Jun 26, 2027 | Janssen Prods |
| Prezcobix | US7700645 | Pseudopolymorphic forms of a HIV protease inhibitor | Dec 26, 2026 | Janssen Prods |
| Prezcobix |
US8518987 (Pediatric) | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug 16, 2024
(Expired) | Janssen Prods |
| Prezcobix | US8518987 | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb 16, 2024
(Expired) | Janssen Prods |
| Prezcobix |
US7470506 (Pediatric) | Fitness assay and associated methods |
Dec 23, 2019
(Expired) | Janssen Prods |
| Prezcobix |
US8597876 (Pediatric) | Method of treating HIV infection |
Dec 23, 2019
(Expired) | Janssen Prods |
| Prezcobix | US7470506 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezcobix | US8597876 | Method of treating HIV infection |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezcobix | US9889115 | Fitness assay and associated methods |
Jun 23, 2019
(Expired) | Janssen Prods |
| Prezcobix |
USRE43596 (Pediatric) | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov 09, 2017
(Expired) | Janssen Prods |
| Prezcobix | USRE43596 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May 09, 2017
(Expired) | Janssen Prods |
| Prezcobix |
USRE42889 (Pediatric) | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr 19, 2017
(Expired) | Janssen Prods |
| Prezcobix |
USRE43802 (Pediatric) | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr 19, 2017
(Expired) | Janssen Prods |
| Prezcobix | USRE42889 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct 19, 2016
(Expired) | Janssen Prods |
| Prezcobix | USRE43802 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct 19, 2016
(Expired) | Janssen Prods |
| Prezcobix |
US5843946 (Pediatric) | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun 01, 2016
(Expired) | Janssen Prods |
| Prezcobix | US5843946 | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec 01, 2015
(Expired) | Janssen Prods |
Cobicistat; Darunavir's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List